RenovoRx (RNXT) Competitors $1.22 -0.12 (-8.96%) Closing price 10/7/2025 04:00 PM EasternExtended Trading$1.21 -0.01 (-0.82%) As of 04:32 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock RNXT vs. GNFT, IPHA, PLX, MIST, SLS, MCRB, TARA, AVTX, NLTX, and CTORShould you be buying RenovoRx stock or one of its competitors? The main competitors of RenovoRx include GENFIT (GNFT), Innate Pharma (IPHA), Protalix BioTherapeutics (PLX), Milestone Pharmaceuticals (MIST), SELLAS Life Sciences Group (SLS), Seres Therapeutics (MCRB), Protara Therapeutics (TARA), Avalo Therapeutics (AVTX), Neoleukin Therapeutics (NLTX), and Citius Oncology (CTOR). These companies are all part of the "pharmaceutical products" industry. RenovoRx vs. Its Competitors GENFIT Innate Pharma Protalix BioTherapeutics Milestone Pharmaceuticals SELLAS Life Sciences Group Seres Therapeutics Protara Therapeutics Avalo Therapeutics Neoleukin Therapeutics Citius Oncology GENFIT (NASDAQ:GNFT) and RenovoRx (NASDAQ:RNXT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, valuation, profitability, analyst recommendations, earnings and dividends. Does the media refer more to GNFT or RNXT? In the previous week, GENFIT's average media sentiment score of 0.00 equaled RenovoRx'saverage media sentiment score. Company Overall Sentiment GENFIT Neutral RenovoRx Neutral Do insiders & institutionals have more ownership in GNFT or RNXT? 2.2% of GENFIT shares are owned by institutional investors. Comparatively, 3.1% of RenovoRx shares are owned by institutional investors. 4.2% of GENFIT shares are owned by company insiders. Comparatively, 9.1% of RenovoRx shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has more volatility & risk, GNFT or RNXT? GENFIT has a beta of 1.18, suggesting that its share price is 18% more volatile than the S&P 500. Comparatively, RenovoRx has a beta of 1.3, suggesting that its share price is 30% more volatile than the S&P 500. Which has stronger earnings & valuation, GNFT or RNXT? GENFIT has higher revenue and earnings than RenovoRx. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGENFIT$76.77M2.58$1.63MN/AN/ARenovoRx$40K1,117.83-$8.81M-$0.38-3.21 Is GNFT or RNXT more profitable? GENFIT's return on equity of 0.00% beat RenovoRx's return on equity.Company Net Margins Return on Equity Return on Assets GENFITN/A N/A N/A RenovoRx N/A -120.68%-89.23% Do analysts prefer GNFT or RNXT? GENFIT presently has a consensus price target of $7.00, suggesting a potential upside of 76.77%. RenovoRx has a consensus price target of $7.50, suggesting a potential upside of 514.75%. Given RenovoRx's stronger consensus rating and higher possible upside, analysts plainly believe RenovoRx is more favorable than GENFIT.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GENFIT 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00RenovoRx 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 SummaryRenovoRx beats GENFIT on 7 of the 11 factors compared between the two stocks. Get RenovoRx News Delivered to You Automatically Sign up to receive the latest news and ratings for RNXT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RNXT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RNXT vs. The Competition Export to ExcelMetricRenovoRxMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$49.10M$3.35B$6.11B$10.65BDividend YieldN/A2.29%5.70%4.74%P/E Ratio-3.2121.4185.5026.85Price / Sales1,117.83466.25621.40135.13Price / CashN/A47.6737.7861.77Price / Book6.4210.0613.136.70Net Income-$8.81M-$52.22M$3.30B$276.44M7 Day Performance-8.96%4.25%3.92%2.48%1 Month Performance7.02%12.50%8.39%8.79%1 Year Performance22.07%26.68%87.22%34.41% RenovoRx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RNXTRenovoRx1.7639 of 5 stars$1.22-9.0%$7.50+514.8%+14.0%$49.10M$40K-3.216GNFTGENFIT1.149 of 5 stars$3.70+1.2%$7.00+89.4%-27.5%$184.75M$76.77M0.00120Gap UpIPHAInnate Pharma2.6647 of 5 stars$1.94+6.6%$6.50+235.1%-4.9%$178.83M$21.77M0.00220PLXProtalix BioTherapeutics2.0021 of 5 stars$2.22+2.8%$15.00+575.7%+145.1%$177.01M$61.95M-17.08200MISTMilestone Pharmaceuticals2.4129 of 5 stars$2.00-1.5%$4.50+125.0%+36.8%$169.98M$1M-2.3830News CoveragePositive NewsSLSSELLAS Life Sciences Group2.2694 of 5 stars$1.61+3.2%$7.00+334.8%+50.8%$169.53M$1M-5.0310News CoveragePositive NewsShort Interest ↓MCRBSeres Therapeutics2.3542 of 5 stars$19.24+2.9%$14.33-25.5%+21.3%$168.45MN/A-4.18330Positive NewsTARAProtara Therapeutics1.7339 of 5 stars$4.35-1.4%$19.60+350.6%+173.9%$167.82MN/A-2.6930News CoveragePositive NewsAVTXAvalo Therapeutics3.2655 of 5 stars$12.71-2.4%$31.67+149.1%+39.9%$167.16M$441K0.0040High Trading VolumeNLTXNeoleukin TherapeuticsN/A$17.71-0.6%N/A-51.4%$166.44MN/A-5.6990High Trading VolumeCTORCitius Oncology3.3286 of 5 stars$2.03flat$6.00+195.6%+74.1%$159.09MN/A0.00N/ANews CoverageGap Down Related Companies and Tools Related Companies GNFT Alternatives IPHA Alternatives PLX Alternatives MIST Alternatives SLS Alternatives MCRB Alternatives TARA Alternatives AVTX Alternatives NLTX Alternatives CTOR Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RNXT) was last updated on 10/8/2025 by MarketBeat.com Staff From Our PartnersBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredU.S. Government Blocked NVIDIA’s Buyout… Here’s WhyThe U.S. government doesn't normally block billion-dollar tech deals. But when NVIDIA tried to acquire this...Behind the Markets | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored"I'm risking my reputation on this"My prediction: Q4 2025 won't just be another seasonal crypto pump. It will be the quarter that sparks a crypto...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RenovoRx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share RenovoRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
